CeriBell, Inc. (NASDAQ:CBLL) Receives Average Rating of “Moderate Buy” from Analysts

Shares of CeriBell, Inc. (NASDAQ:CBLL) have been given an average rating of “Moderate Buy” by the seven brokerages that are covering the stock, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $24.6667.

CBLL has been the topic of a number of research reports. TD Cowen restated a “buy” rating on shares of CeriBell in a research note on Tuesday, December 9th. Raymond James Financial started coverage on shares of CeriBell in a research report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 target price on the stock. JPMorgan Chase & Co. reduced their price target on shares of CeriBell from $21.00 to $17.00 and set an “overweight” rating for the company in a research report on Wednesday, November 5th. BTIG Research reissued a “buy” rating and set a $30.00 price target on shares of CeriBell in a report on Wednesday, January 28th. Finally, Canaccord Genuity Group upped their price objective on CeriBell from $29.00 to $30.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th.

CeriBell Stock Performance

Shares of CBLL stock opened at $20.57 on Thursday. The stock’s 50-day moving average is $21.38 and its two-hundred day moving average is $15.79. The company has a debt-to-equity ratio of 0.12, a quick ratio of 12.25 and a current ratio of 12.65. CeriBell has a 1 year low of $10.01 and a 1 year high of $26.04. The firm has a market cap of $763.15 million, a price-to-earnings ratio of -13.62 and a beta of 1.03.

Insiders Place Their Bets

In related news, CTO Raymond Woo sold 11,112 shares of the stock in a transaction on Friday, January 2nd. The stock was sold at an average price of $21.18, for a total transaction of $235,352.16. Following the completion of the sale, the chief technology officer directly owned 167,317 shares of the company’s stock, valued at $3,543,774.06. This trade represents a 6.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Josef Parvizi sold 25,000 shares of CeriBell stock in a transaction on Monday, December 15th. The shares were sold at an average price of $21.49, for a total transaction of $537,250.00. Following the completion of the transaction, the director owned 772,652 shares in the company, valued at approximately $16,604,291.48. This trade represents a 3.13% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 369,656 shares of company stock valued at $7,281,615. 20.10% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in CeriBell during the 3rd quarter worth approximately $33,000. CWM LLC boosted its stake in shares of CeriBell by 1,178.5% in the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock valued at $40,000 after buying an additional 1,697 shares in the last quarter. Tower Research Capital LLC TRC grew its holdings in CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after acquiring an additional 1,801 shares during the period. Ameritas Investment Partners Inc. raised its position in CeriBell by 97.5% in the second quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock worth $48,000 after acquiring an additional 1,256 shares in the last quarter. Finally, Larson Financial Group LLC lifted its holdings in CeriBell by 1,403.1% in the fourth quarter. Larson Financial Group LLC now owns 2,871 shares of the company’s stock valued at $63,000 after acquiring an additional 2,680 shares during the period.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.